Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double Blind, Multi Center, Multinational, Placebo Controlled, Single Parallel Escalating Dose Safety and Efficacy Study of ACT017 Used as an Add on Therapy on Top of Standard of Care of Acute Ischemic Stroke

Next Previous
X
Search
Trial Profile

Randomized, Double Blind, Multi Center, Multinational, Placebo Controlled, Single Parallel Escalating Dose Safety and Efficacy Study of ACT017 Used as an Add on Therapy on Top of Standard of Care of Acute Ischemic Stroke

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glenzocimab (Primary)
  • Indications Stroke
  • Focus Adverse reactions
  • Acronyms ACTIMIS
  • Sponsors Acticor Biotech

    • Most Recent Events

    • 01 Feb 2024 Results published in the Lancet Neurology
    • 31 Aug 2023 Post-hoc analysis results assessing the imaging data using Artificial Intelligence (AI) from its phase 1b/2a ACTIMIS study, published in the Media Release.
    • 09 May 2022 According to an Acticor Biotech media release, results from this study will be presented at the at the 8th European Stroke Organisation Conference (ESOC), 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top